sapropterin dihydrochloride
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonurias
Conditions
Phenylketonurias
Trial Timeline
Nov 1, 2005 → Jun 1, 2006
NCT ID
NCT00225615About sapropterin dihydrochloride
sapropterin dihydrochloride is a phase 3 stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is completed. This product is registered under clinical trial identifier NCT00225615. Target conditions include Phenylketonurias.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00484991 | Pre-clinical | Completed |
| NCT01274026 | Pre-clinical | Completed |
| NCT01141595 | Pre-clinical | Completed |
| NCT00838435 | Phase 3 | Completed |
| NCT00445978 | Phase 2 | Completed |
| NCT00403494 | Phase 2 | Completed |
| NCT00332189 | Phase 3 | Completed |
| NCT00225615 | Phase 3 | Completed |
| NCT00104260 | Phase 2 | Completed |
Competing Products
7 competing products in Phenylketonurias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |
| sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | BioMarin Pharmaceutical | Phase 3 | 74 |
| Pegvaliase-Pqpz | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Palynziq | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Sapropterin Dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |